Switzerland approves vaccine that targets two Covid variants
Moderna's new Covid-19 vaccine has been given temporary approval in Switzerland.
Copyright 2022 The Associated Press. All Rights Reserved
The Swiss medicaments regulator Swissmedic has given temporary approval for a Covid-19 vaccine from Moderna that has been adapted to give protection against two different strains of the virus.
This content was published on
1 minute
swissinfo.ch/mga
Español
es
Suiza aprueba vacuna contra dos variantes de COVID
The ‘Spikevax Bivalent Original/Omicron’ is designed to be administered in two 0.5ml doses.
It contains 25 micrograms of the original Spikevax mRNA-1273 plus 25 micrograms of a different mRNA that targets the Omicron variant (BA.1 and BA.4/5).
On Monday, Swissmedic saidExternal link that in trials the dual vaccine had achieved higher antibody concentrations against the Omicron variant than the original Spikevax, “with comparable side-effects”.
Those side-effects can include irritation, redness or swelling at the injection site, fatigue, headache, chills or nausea.
The Human Medicines Expert Committee has also given its separate seal of approval for the new vaccine, said Swissmedic.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
French cross-border workers in Switzerland fear “discriminatory” unemployment reform
This content was published on
In the French region around Geneva, cross-border workers are protesting proposals to cut unemployment benefits for those working in Switzerland.
Swan infected with bird flu in central Switzerland
This content was published on
Switzerland has reported its first bird flu case of the season. A swan found dead in central Switzerland tested positive for the H5N1 virus.
Swiss researchers identify gene variants linked to cancer progression
This content was published on
ETH Zurich researchers explored genetic mutations’ effects on cell function and their role in cancer development and treatment using CRISPR/Cas techniques.
Explosion at Swiss company Givaudan’s US plant leaves two dead
This content was published on
Swiss flavour and fragrance maker Givaudan reported that an explosion at its Kentucky plant resulted in two deaths and several injuries.
Swisscom’s Vodafone Italia takeover cleared by Italian telecoms authority
This content was published on
Swisscom is one step closer to its planned acquisition of Vodafone Italia, as the Italian communications regulator has approved the €8 billion deal.
Swiss parliamentary committee proposes foreign aid cuts and military funding boost
This content was published on
A committee of the Swiss House of Representatives has proposed increasing funds for the military and agriculture while reducing foreign aid and asylum.
Swiss Rolex Submariner watches reach nearly $50 billion in total market value
This content was published on
The total market value of all Rolex Submariner watches ever made is nearly $50 billion, based on newly released production data.
Swiss Jew wrongfully detained due to prosecutor’s ‘bias’
This content was published on
A Jewish Swiss man was detained after the prosecutor argued he might flee to Israel. The Federal Court said this implies bias due to his Jewish faith.
US reportedly scrutinises Russian accounts UBS took over from Credit Suisse
This content was published on
The US is investigating Russian clients acquired by UBS during its takeover of Credit Suisse, according to three sources familiar with the matter.
WTO plans to reappoint Okonjo-Iweala before Trump swears in
This content was published on
Some member states of the World Trade Organization may seek to reappoint Director-General Ngozi Okonjo-Iweala, according to a document released on Tuesday.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Switzerland gives green light to Moderna’s Covid vaccine for 6-11 year olds
This content was published on
The Swiss medical regulator Swissmedic has approved Moderna’s Spikevax Covid-19 vaccine for use by children aged 6 to 11 years.
Switzerland approves its first protein-based Covid vaccine
This content was published on
The Swiss medical regulator has approved the Nuvaxovid vaccine for adults making it the fourth Covid-19 vaccine authorised in the country.
Too many Covid doses: Switzerland’s vaccine conundrum
This content was published on
Switzerland is sitting on around 38 million excess Covid-19 vaccine doses to be used by the end of 2022. What will it do with them?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.